Technical Analysis for ALIM - Alimera Sciences, Inc.
|Grade||Last Price||% Change||Price Change|
ALIM closed up 1.0 percent on Friday, November 16, 2018, on 14 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It ran into resistance at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.
|Weak or Absent||Flat||Down||Down|
|See historical ALIM trend table...|
|Date||Alert Name||Type||% Chg|
|Nov 16||200 DMA Resistance||Bearish||0.00%|
|Nov 16||20 DMA Resistance||Bearish||0.00%|
|Nov 16||50 DMA Resistance||Bearish||0.00%|
|Nov 16||180 Bearish Setup||Bearish Swing Setup||0.00%|
|Nov 16||Narrow Range Bar||Range Contraction||0.00%|
|Nov 16||NR7||Range Contraction||0.00%|
|Nov 16||NR7-2||Range Contraction||0.00%|
|Nov 16||Gapped Up||Strength||0.00%|
|Nov 15||Narrow Range Bar||Range Contraction||1.00%|
|Nov 15||NR7||Range Contraction||1.00%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company's principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye to a placement site that takes advantage of the eye's natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME; and in Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is based in Alpharetta, Georgia.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ALIM news...
|52 Week High||1.38|
|52 Week Low||0.74|
|200-Day Moving Average||1.0116|
|50-Day Moving Average||1.0177|
|20-Day Moving Average||1.0198|
|10-Day Moving Average||1.051|
|Average True Range||0.0669|
|Chandelier Exit (Long, 3 ATRs )||0.9493|
|Chandelier Exit (Short, 3 ATRs )||1.1007|
|Upper Bollinger Band||1.1332|
|Lower Bollinger Band||0.9064|
|Percent B (%b)||0.46|
|MACD Signal Line||0.0135|
|Market Cap||69.74 Million|
|Num Shares||69 Million|
|Price-to-Earnings (P/E) Ratio||-2.59|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||1.04|
|Resistance 3 (R3)||1.04||1.04||1.04|
|Resistance 2 (R2)||1.04||1.03||1.04||1.03|
|Resistance 1 (R1)||1.02||1.02||1.02||1.02||1.03|
|Support 1 (S1)||1.00||1.01||1.00||1.00||0.99|
|Support 2 (S2)||1.00||1.00||1.00||0.99|
|Support 3 (S3)||0.98||1.00||0.99|
|Support 4 (S4)||0.98|